Guidelines under development
Guidelines
The AAN is currently developing guidelines on the following topics.
To submit an idea for a future guideline, complete the topic nomination form below. Before you submit a topic, preview the list of questions on the form and gather the required information for your nomination. All topics are reviewed by the Guidelines Subcommittee. For more information, reach out to guidelines@aan.com.
Upcoming public comment for guidelines and measures in development
Draft guidelines:
Complementary and integrative medicine for migraine prevention in children, adolescents, and adults (Q4 2025)
Treatment of essential tremor protocol (update, nonpharmacologic interventions) (Q4 2025)
Draft measures:
None at this time
TOPIC |
TITLE |
STAGE OF DEVELOPMENT |
ESTIMATED PUBLICATION |
| Brain Injury and Death |
None at this time |
N/A |
N/A |
| Child Neurology |
Efficacy and Tolerability of Disease-Modifying Therapies for Children with Spinal Muscular Atrophy |
Mid-stage |
Q1 2027 |
| Epilepsy and Seizures |
Management of Functional Seizures |
Late-stage |
Q1 2026 |
| Epilepsy and Seizures |
Antiseizure Medication Blood Levels During Pregnancy and Breastfeeding: A Practice Guideline Update for People with Epilepsy of Childbearing Potential (Update) |
Early-stage |
Q1 2028 |
| Geriatric Neurology |
Etiologic Diagnosis of Dementia (Update) |
Mid-stage |
Q3 2027 |
| Headache |
Pharmacologic Treatment for Migraine Prevention in Adults (Update) |
Late-stage |
Q1 2026 |
| Headache |
Complementary and Integrative Medicine for Migraine Prevention in Adults, Children, and Adolescents (Update) |
Mid-stage |
Q3 2027 |
|
Movement Disorders |
Treatment of Essential Tremor (Update, Non-pharmacologic interventions) |
Early-stage |
Q4 2028 |
| Multiple Sclerosis | None at this time | N/A | N/A |
|
Neuromuscular Disorders |
None at this time |
N/A |
N/A |
| Stroke and Vascular Neurology | Recanalization Therapy for Acute Ischemic Stroke | Mid-stage | Q4 2026 |
|
Other Neurology Topics |
Neurologic Adverse Events Following Immunizations (Update) |
Late-stage |
Q1 2026 |